---
title: "uniQure N.V. (QURE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/QURE.US.md"
symbol: "QURE.US"
name: "uniQure N.V."
industry: "Biotechnology"
datetime: "2026-05-20T08:16:15.009Z"
locales:
  - [en](https://longbridge.com/en/quote/QURE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/QURE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/QURE.US.md)
---

# uniQure N.V. (QURE.US)

## Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.uniqure.com](https://www.uniqure.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.80)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 218 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.44% |  |
| Net Profit YoY | 4.00% |  |
| P/B Ratio | 10.43 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1557136204.65 |  |
| Revenue | 18093000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -228.24% | E |
| Profit Margin | -1154.42% | E |
| Gross Margin | -762.80% | E |
| Revenue YoY | -10.44% | E |
| Net Profit YoY | 4.00% | C |
| Total Assets YoY | 28.63% | A |
| Net Assets YoY | 343.34% | A |
| Cash Flow Margin | 82.40% | C |
| OCF YoY | -10.44% | E |
| Turnover | 0.03 | E |
| Gearing Ratio | 80.82% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - uniQure N.V.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "4.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "10.43",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1557136204.65",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "18093000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-228.24%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1154.42%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-762.80%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.44%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "4.00%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "28.63%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "343.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "82.40%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-10.44%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "80.82%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.46 | 418/386 | - | - | - |
| PB | 10.43 | 392/386 | 23.40 | 6.69 | 5.53 |
| PS (TTM) | 86.06 | 252/386 | 101.68 | 78.11 | 45.02 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 57% |
| Overweight | 1 | 7% |
| Hold | 4 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.69 |
| Highest Target | 95.68 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/QURE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/QURE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/QURE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/QURE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**